Immuno Aktiengesellschaft

Baxter Aktiengesellschaft

Tempo G

Bio-Products & Bio-Engineering Ag

Josef Mannhalter

Heinz Leibl

Martha Eibl

Hermann Wolf

Regine Tomasits

Johann J Eibl

Yendra Linnau

Martha Leibl

A method for the separation of IgG and IgA from an immunoglobulin-containing starting material is described, whereby the method is characterized in that (i) IgG and optionally IgA are adsorbed to a solid inorganic carrier material, (ii) IgA is isolated from the eluate, optionally after selective desorption, whereas IgG remains on the carrier material, and optionally (iii) IgG is isolated from the adsorbate. Furthermore, an IgA preparation is disclosed which demonstrates a low tendency to form aggregates.

Process for isolating IgG and IgA

The invention concerns an immunogenic construct comprising as components (i) an inactive flavivirus or a derivative thereof, and (ii) at least one immunogenic component which is bonded to the flavivirus or adsorbed therewith. The invention further concerns a process for preparing the immunogenic construct and its use as a vaccine.

Immunogenic constructs comprising flaviviruses or flavivirus derivatives

An adjuvant is described which comprises an iron compound in colloidal form as well as a pharmaceutical composition which comprises this adjuvant together with at least a protein and/or peptide and/or polysaccharide and/or a nucleic acid derived from a virus, bacterium and/or a parasite. The adjuvant according to the invention and the pharmaceutical composition comprising this adjuvant are suitable for prophylactic or therapeutic treatment of illnesses caused by various pathogens.

Adjuvant based on colloidal iron compounds

Inflammation can be treated or prevented altogether by administering a preparation comprising IgA. These preparations also can effect immunomodulation. Preferably, the preparation includes multimeric IgA and is essentially free of IgG in its various forms. Other compounds, such as antibiotics, antiphlogistic agents and antacids, also may be administered. Immunoglobulin A may also be used in vaccines to prevent inflammation. Additionally, an improved assay for evaluating anti-inflammatory activity is provided.

Composition and method for preventing and treating inflammation with

A virus-safe monomeric human IgA is described which is essentially free of IgG. The IgA according to the invention is obtainable according to a process in which (a) an IgA-containing fraction is subjected to a purification such that a monomeric IgA which is essentially free of IgG is obtained and (b) the obtained product is subjected to a process for the inactivation of viruses.

Growing community of inventors

Vienna, Austria

Josef Mannhalter